Senseonics Holdings, Inc.
Senseonics Holdings, Inc. (SENS) develops and commercialises the Eversense family of long‑term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s differentiated technology focuses on an implanted sensor that can remain under the skin for months, combined with a removable transmitter and mobile app to deliver glucose readings and alerts. Revenue comes mainly from sales of sensors, transmitters, and related services, though the business can be sensitive to reimbursement, clinical adoption and distribution partnerships. With a market cap of about $310.8M, Senseonics operates in a competitive market that includes non‑implantable CGM leaders and emerging entrants. Key investor considerations include clinical performance, regulatory milestones, payer coverage, and the company’s cash position because medical device growth often requires sustained investment. This summary is educational only and not personal financial advice; values can fall as well as rise and prospective investors should do their own research or speak to a qualified adviser.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Senseonics stock, predicting its price could rise to $2.
Financial Health
Senseonics has low sales and profitability, indicating challenges in its financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SENS
Wearable Health Stocks: Growth Potential vs Competition
Apple's recent FDA clearance for its Apple Watch hypertension feature marks a major step in wearable medical technology. This development opens up investment opportunities in the broader ecosystem of connected health devices and remote patient monitoring services.
Published: September 12, 2025
Explore BasketAt-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: September 1, 2025
Explore BasketWearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: August 21, 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Long‑life CGM thesis
Eversense’s multi‑month implantable sensor targets convenience and adherence advantages versus short‑term sensors, though clinical acceptance and payer reimbursement remain crucial.
Diabetes market scale
The global diabetes population creates significant demand for monitoring solutions; market growth could support niche players, but larger incumbents intensify competition.
Regulatory and adoption
Regulatory approvals and distribution partnerships drive uptake, while capital needs and device performance can cause share price volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
